共 50 条
Risk of Advanced Age-Related Macular Degeneration after Cataract Surgery in the Age-Related Eye Disease Study AREDS Report 25
被引:111
|作者:
Chew, Emily Y.
[1
]
Sperduto, Robert. D.
[3
]
Milton, Roy C.
[3
]
Clemons, Traci E.
[3
]
Gensler, Gary R.
[3
]
Bressler, Susan B.
[2
]
Klein, Ronald
[4
]
Klein, Barbara E. K.
[4
]
Ferris, Frederick L., III
[1
]
机构:
[1] NEI, Bethesda, MD 20892 USA
[2] Johns Hopkins Wilmer Eye Inst, Baltimore, MD USA
[3] EMMES Corp, Rockville, MD USA
[4] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA
基金:
美国国家卫生研究院;
关键词:
BEAVER DAM;
MACULOPATHY;
ASSOCIATION;
EXTRACTION;
D O I:
10.1016/j.ophtha.2008.09.019
中图分类号:
R77 [眼科学];
学科分类号:
100212 ;
摘要:
Purpose: To assess the risk of advanced age-related macular degeneration (AMD) developing after cataract surgery. Design: Cohort study. Participants: Four thousand five hundred seventy-seven participants (8050 eyes) from a multicenter, controlled, randomized clinical trial, the Age-Related Eye Disease Study (AREDS). Methods: Development of advanced AMD, either neovascular (NV) AMD or geographic atrophy (GA), was evaluated with annual fundus photographs, and history of cataract surgery was assessed every 6 months. Cox proportional hazard models with time-dependent covariates were conducted for NV AMD and GA separately. Main Outcome Measures: Neovascular AMD, GA, and central GA (CGA; involving the center of the macula). Results: The Cox proportional hazards model of right eyes showed nonsignificant hazard ratios of 1.20 (95% confidence interval [CI], 0.82-1.75) for NV AMD, 0.80 (95% CI, 0.61-1.06) for GA, and 0.87 (95% CI, 0.64-1.18) for CGA. Similar results were obtained for left eyes: 1.07 (95% CI, 0.72-1.58) for NV AMD, 0.94 (95% CI, 0.71-1.25) for GA, and 0.86 (95% CI, 0.63-1.19) for CGA. For participants with advanced AMD in 1 eye (AREDS category 4), the hazard ratios for fellow eyes were 1.08 (95% CI, 0.65-1.72) for NV AMD and 0.98 (95% CI, 0.64-1.49) for CGA. Conclusions. The AREDS results show-ad no clear effect of cataract surgery on the risk of progression to advanced AMD. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009;116:297-303 (C) 2009 by the American Academy of Ophthalmology.
引用
收藏
页码:297 / 303
页数:7
相关论文